Pathogenetic substantiation and effectiveness of vildagliptin use inpatients with diabetes mellitus type 2
Insulin resistance in muscle and liver and β-cell failure represent the core pathophysiologic defects in type 2 diabetes. Now it isrecognized that the β-cell failure occurs much earlier and is more severe than previously thought. As a result, earlier and more aggressive new therapy is needed to achi...
Format: | Article |
---|---|
Language: | English |
Published: |
Endocrinology Research Centre
2009-09-01
|
Series: | Ожирение и метаболизм |
Subjects: | |
Online Access: | https://www.omet-endojournals.ru/jour/article/view/5241 |
Similar Items
-
Lechenie sakharnogo diabeta 2 tipa ingibitorami dipeptidilpeptidazy-4
Published: (2010-09-01) -
Dipeptidyl Peptidase (DPP)-IV Inhibitors with Antioxidant Potential Isolated from Natural Sources: A Novel Approach for the Management of Diabetes
by: Anand-Krishna Singh, et al.
Published: (2021-06-01) -
Predictive Clinical Parameters and Glycemic Efficacy of Vildagliptin Treatment in Korean Subjects with Type 2 Diabetes
by: Jin-Sun Chang, et al.
Published: (2013-02-01) -
Comparative effects of incretin-based therapy on doxorubicin-induced nephrotoxicity in rats: the role of SIRT1/Nrf2/NF-κB/TNF-α signaling pathways
by: Sandy R. Botros, et al.
Published: (2024-02-01) -
Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential
by: Nasser Mikhail
Published: (2008-12-01)